Tenapanor
Showing 1 - 25 of 27
IBS, IBS - Irritable Bowel Syndrome Trial (Tenapanor)
Not yet recruiting
- IBS
- IBS - Irritable Bowel Syndrome
- Tenapanor
- (no location specified)
Aug 10, 2023
Irritable Bowel Syndrome With Constipation (IBS-C) Trial in Foley (Tenapanor)
Enrolling by invitation
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Tenapanor
-
Foley, AlabamaG & L Research, LLC
Jun 13, 2023
Irritable Bowel Syndrome With Constipation (IBS-C) Trial in Foley (Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo)
Recruiting
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Tenapanor 50 MG
- +2 more
-
Foley, AlabamaG & L Research, LLC
Nov 30, 2022
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia Trial in Lauderdale Lakes (Tenapanor)
Completed
- Chronic Kidney Disease Requiring Chronic Dialysis
- Hyperphosphatemia
- Tenapanor
-
Lauderdale Lakes, FloridaSouth Florida Research Institute
Sep 28, 2022
Hyperphosphatemia, End Stage Renal Disease Trial in Houston (Tenapanor, Sevelamer Carbonate)
Completed
- Hyperphosphatemia
- End Stage Renal Disease
- Tenapanor
- Sevelamer Carbonate
-
Houston, CaliforniaArdelyx Site #509
Jan 5, 2022
Constipation Predominant Irritable Bowel Syndrome Trial in Miami (Tenapanor)
Completed
- Constipation Predominant Irritable Bowel Syndrome
- Tenapanor
-
Miami, FloridaArdelyx Clinical Site
Aug 25, 2020
Hyperphosphatemia Trial in Bronx, Winston-Salem (Tenapanor, Placebo, Sevelamer Carbonate)
Completed
- Hyperphosphatemia
- Tenapanor
- +2 more
-
Bronx, New York
- +1 more
Aug 18, 2020
End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD Trial in Tempe, Denver, Minneapolis (AZD1722 (in-patient), Placebo
Completed
- End Stage Renal Disease
- +2 more
- AZD1722 (in-patient)
- +3 more
-
Tempe, Arizona
- +2 more
Aug 6, 2020
Hyperphosphatemia Trial in United States (Tenapanor, Placebo, Phosphate Binder Agents)
Completed
- Hyperphosphatemia
- Tenapanor
- +2 more
-
Huntsville, Alabama
- +47 more
Aug 31, 2020
Constipation Predominant Irritable Bowel Syndrome Trial in United States (AZD1722, Placebo)
Completed
- Constipation Predominant Irritable Bowel Syndrome
- AZD1722
- Placebo
-
Boulder, Colorado
- +3 more
Mar 31, 2020
Constipation Predominant Irritable Bowel Syndrome Trial in United States (Tenapanor, Placebo)
Completed
- Constipation Predominant Irritable Bowel Syndrome
- Tenapanor
- Placebo
-
Dothan, Alabama
- +116 more
Apr 10, 2020
Constipation Predominant Irritable Bowel Syndrome Trial in United States (Tenapanor, Placebo)
Completed
- Constipation Predominant Irritable Bowel Syndrome
- Tenapanor
- Placebo
-
Birmingham, Alabama
- +110 more
Apr 10, 2020
Hyperphosphatemia Trial in Tsukuba (KHK7791, Placebo)
Completed
- Hyperphosphatemia
- KHK7791
- Placebo
-
Tsukuba, Ibaraki, JapanKikuchi medical clinic
Sep 7, 2021
Hyperphosphatemia Trial in Kanoya (KHK7791)
Active, not recruiting
- Hyperphosphatemia
-
Kanoya, Kagoshima, JapanMedical Corporation Seijinkai Ikeda Hospital
Sep 7, 2021
Chronic Kidney Disease, Type 2 Diabetes Trial in Denver (AZD1722, Placebo)
Completed
- Chronic Kidney Disease
- Type 2 Diabetes Mellitus
- AZD1722
- Placebo
-
Denver, ColoradoCreekside Endocrine Associates PC
May 9, 2020
Constipation Predominant Irritable Bowel Syndrome Trial in United States (RDX5791)
Completed
- Constipation Predominant Irritable Bowel Syndrome
-
San Diego, California
- +15 more
Sep 25, 2019